PROFESSIONAL EDITION

The largest community of pharma leaders

Sesen Bio Announces Retirement of Leslie L. Dan

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company’s Board of Directors, effective July 16, 2019. With the retirement of Mr. Dan, the Company’s Board of Directors will be comprised of five directors of which four are independent. The Company’s Board of Directors intends to fill the director vacancy….

 

 

http://www.businesswire.com/news/home/20190717005730/en/Sesen-Bio-Announces-Retirement-Leslie-L.-Dan

Recent Articles